Neoadjuvant Clinical Trials

124 recruitingLast updated: June 17, 2026

There are 124 actively recruiting neoadjuvant clinical trials across 17 countries. Studies span Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1, Phase 4. Top locations include Guangzhou, Guangdong, China, Shanghai, Shanghai Municipality, China, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Neoadjuvant Trials at a Glance

124 actively recruiting trials for neoadjuvant are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Phase 2 with 57 trials, with the heaviest enrollment activity in Guangzhou, Shanghai, and Beijing. Lead sponsors running neoadjuvant studies include Sun Yat-sen University, Sixth Affiliated Hospital, Sun Yat-sen University, and Tongji Hospital.

Browse neoadjuvant trials by phase

Treatments under study

About Neoadjuvant Clinical Trials

Looking for clinical trials for Neoadjuvant? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neoadjuvant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neoadjuvant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 124 trials

Recruiting
Phase 2

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Primary Peritoneal CancerFallopian Tube CancerNeoadjuvant+1 more
AbbVie140 enrolled66 locationsNCT06890338
Recruiting
Phase 2

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8+26 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04771520
Recruiting

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

Neoadjuvant TherapyNon-small Cell Lung CancerImmunotherapy+1 more
Peking University People's Hospital80 enrolled1 locationNCT07359040
Recruiting
Phase 2

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Neoadjuvant TreatmentThyroid Cancer
M.D. Anderson Cancer Center45 enrolled2 locationsNCT06959511
Recruiting
Not Applicable

Intravital Microscopy in Human Solid Tumors

Malignant Brain NeoplasmMalignant Solid NeoplasmAnatomic Stage IV Breast Cancer AJCC v8+20 more
Mayo Clinic85 enrolled1 locationNCT03823144
Recruiting
Phase 2

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)Neoadjuvant TherapyHead and Neck Squamous Cell Carcinoma+1 more
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine182 enrolled1 locationNCT07601737
Recruiting
Phase 3

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer

Rectal CancerRadiotherapyImmunotherapy+1 more
Tao Zhang444 enrolled1 locationNCT07113275
Recruiting

Evaluation of the Administration of Artificial Nutrition by Feeding Jejunostomy During Neoadjuvant Treatment on Postoperative Morbidity in the Context of Esophageal or Stomach Cancer

Esophageal CancerNeoadjuvant TreatmentMalnourished+1 more
University Hospital, Bordeaux670 enrolled1 locationNCT07584577
Recruiting
Phase 2Phase 3

Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.

Radiotherapy Side EffectNeoadjuvant TherapyChemotherapy+8 more
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos400 enrolled1 locationNCT06758830
Recruiting

Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE

NSCLCNeoadjuvant ChemoimmunotherapyCT
Samsung Medical Center150 enrolled1 locationNCT07559123
Recruiting
Phase 1

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Locally Advanced Gastroesophageal Junction AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaStage IV Colorectal Cancer AJCC v8+26 more
Roswell Park Cancer Institute45 enrolled1 locationNCT04511039
Recruiting

RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC

Robotic SurgeryStage IIB-III NSCLCNeoadjuvant Chemoimmunotherapy+1 more
Shanghai Chest Hospital100 enrolled10 locationsNCT07541521
Recruiting
Not Applicable

Digital Mind-Body Therapy for Neoadjuvant Breast Cancer

Neoadjuvant Therapy
Fudan University66 enrolled1 locationNCT07541664
Recruiting

Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC

Stage IIB-III NSCLCNeoadjuvant ChemoimmunotherapyRobotic Pulmonary Resection
Shanghai Chest Hospital200 enrolled10 locationsNCT07528066
Recruiting

Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer

Breast CancerNeoadjuvant TherapyInvasive Breast Carcinoma+2 more
Atlas University80 enrolled1 locationNCT07289282
Recruiting
Phase 2

CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer

Neoadjuvant TherapyLocally Advanced Rectal Cancer
Fudan University192 enrolled1 locationNCT06281405
Recruiting

FAP-targeted PET/NIR in Lung Malignant Tumors

Neoadjuvant TherapyNon-small Cell Lung CancerPET/CT
Peking University People's Hospital200 enrolled1 locationNCT07498933
Recruiting
Phase 2

Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC

Neoadjuvant TherapyKRAS G12C MutationResectable NSCLC+1 more
Jianxing He30 enrolled3 locationsNCT07492342
Recruiting

Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer(NSCLC)

Neoadjuvant TherapyNSCLC
Qian Chu500 enrolled2 locationsNCT07388771
Recruiting
Phase 3

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Renal Cell CarcinomaNeoadjuvant
ZHOU FANGJIAN298 enrolled8 locationsNCT05738694